Home › Funds › NVP Associates, LLC › ZBIO
NVP Associates, LLC position in ZBIO
ZENAS BIOPHARMA INC · Health Care
NVP Associates, LLC reported holding 1,838,482 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$49.6M, representing 17.59% of its reported portfolio and ranking #3 among its reported holdings. NVP Associates, LLC has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How NVP Associates, LLC's ZBIO position evolved
NVP Associates, LLC first disclosed a stake in ZBIO in Q3 2024 at 1,838,482 shares (US$31.1M). The position peaked in Q4 2025 at 1,838,482 shares, worth US$66.8M. Across 9 filings, NVP Associates, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,838,482 shares valued at US$49.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 1.84M | $31.11M | New |
| Q4 2024 | 1.84M | $15.06M | Hold |
| Q1 2025 | 1.84M | $14.52M | Hold |
| Q2 2025 | 1.84M | $17.81M | Hold |
| Q3 2025 | 1.84M | $40.81M | Hold |
| Q4 2025 | 1.84M | $66.76M | Hold |
| Q1 2026 | 1.84M | $35.94M | Hold |
| Q2 2026 | 1.84M | $46.66M | Hold |
| Q3 2026 | 1.84M | $49.58M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 63 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M sh · $102.11M · Q2 2026
- Enavate Sciences GP, LLC 3.92M sh · $99.47M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M sh · $64.41M · Q3 2026
- Fairmount Funds Management LLC 2.36M sh · $59.87M · Q2 2026
- Context Capital Management, LLC 31.05M sh · $39.70M · Q3 2026
- EcoR1 Capital, LLC 789.50K sh · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K sh · $14.55M · Q2 2026
- Rock Springs Capital Management LP 502.08K sh · $12.74M · Q2 2026
- NEXTBio Capital Management LP 426.74K sh · $11.51M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 334.06K sh · $9.01M · Q3 2026
More on NVP Associates, LLC
FAQ
How long has NVP Associates, LLC held ZBIO?
NVP Associates, LLC has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is NVP Associates, LLC's current position in ZBIO?
As of Q3 2026, NVP Associates, LLC holds 1.84M shares of ZBIO (ZENAS BIOPHARMA INC), valued at $49.58M, representing 17.59% of its reported portfolio and ranking #3.
Has NVP Associates, LLC been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), NVP Associates, LLC held unchanged its position in ZBIO. The position peaked in Q4 2025 at 1.84M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.